Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics EPS Diluted (Quarterly) : 1.897 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.897 |
| March 31, 2026 | 1.221 |
| December 31, 2025 | -1.203 |
| September 30, 2025 | 1.432 |
| June 30, 2025 | 1.330 |
| March 31, 2025 | 0.9325 |
| December 31, 2024 | 1.062 |
| September 30, 2024 | 1.053 |
| June 30, 2024 | 0.7216 |
| March 31, 2024 | 0.596 |
| December 31, 2023 | 0.6516 |
| September 30, 2023 | 0.6103 |
| June 30, 2023 | 0.5598 |
| March 31, 2023 | 0.2873 |
| December 31, 2022 | 0.4163 |
| September 30, 2022 | 0.4422 |
| June 30, 2022 | 0.1595 |
| March 31, 2022 | 0.4255 |
| December 31, 2021 | 0.4629 |
| September 30, 2021 | 1.476 |
| June 30, 2021 | 0.6195 |
| March 31, 2021 | 0.1878 |
| December 31, 2020 | 0.5042 |
| September 30, 2020 | 0.2548 |
| June 30, 2020 | 0.187 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0445 |
| December 31, 2019 | -0.2439 |
| September 30, 2019 | -0.1712 |
| June 30, 2019 | -0.1006 |
| March 31, 2019 | 0.0122 |
| December 31, 2018 | -0.0147 |
| September 30, 2018 | -0.1935 |
| June 30, 2018 | -0.16 |
| March 31, 2018 | -0.1925 |
| December 31, 2017 | 0.85 |
| September 30, 2017 | 0.02 |
| June 30, 2017 | -0.23 |
| March 31, 2017 | -0.26 |
| December 31, 2016 | -0.21 |
| September 30, 2016 | -0.23 |
| June 30, 2016 | -0.21 |
| March 31, 2016 | -0.16 |
| December 31, 2015 | 0.03 |
| September 30, 2015 | -0.19 |
| June 30, 2015 | 0.02 |
| March 31, 2015 | -0.12 |
| December 31, 2014 | -0.04 |
| September 30, 2014 | -0.16 |
| June 30, 2014 | -0.13 |
| March 31, 2014 | -0.22 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Incyte Corp. | 2.812 |
| Neurocrine Biosciences, Inc. | 1.386 |
| AVITA Medical, Inc. | -0.2492 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 229.91M |
| Revenue (Quarterly) | 481.00M |
| Total Expenses (Quarterly) | 251.09M |
| Enterprise Value | 14.25B |
| Gross Profit Margin (Quarterly) | 77.40% |
| Profit Margin (Quarterly) | 47.80% |
| Earnings Yield | 3.08% |
| Operating Earnings Yield | 7.18% |
| Normalized Earnings Yield | 5.012 |